Alerta

一种ALO@F127-MOF纳米复合物及其制备方法和应用

Resumen de: CN121868265A

本发明属于生物医药技术领域，具体提供了一种ALO@F127‑MOF纳米复合物及其制备方法和应用。所述ALO@F127‑MOF纳米复合物以具有普朗尼克F‑127涂层的UiO‑66‑NH2 MOF作为纳米载体，苦豆碱负载于所述纳米载体上。将该纳米复合物用于ALI的治疗，有效改善了中药苦豆碱的溶解度、稳定性和生物利用度，实现了苦豆碱的持续释放、ROS中和以及有效靶向的协同效应。基于雾化的递送方法确保了更好的氧合、更低的全身毒性和更优的肺部沉积。本发明为无创急性肺损伤治疗提供了新的治疗方法。

一种通过鼻腔途径实现大脑靶向的脂质纳米颗粒及其递送方法与应用

Resumen de: CN121868249A

本发明公开了一种通过鼻腔途径实现大脑靶向的脂质纳米颗粒及其递送方法与应用。所述脂质纳米颗粒其原料包括肽基可离子化脂质、辅助磷脂、甾族脂质、聚乙二醇脂质；其中，肽基可电离脂质的结构式如式I所示，肽基可离子化脂质占总脂质的摩尔百分比为45‑65%；辅助磷脂占总脂质的摩尔百分比为10‑20%，甾族脂质占总脂质的摩尔百分比为30‑50%，聚乙二醇脂质占总脂质的摩尔百分比为1‑5%。将核酸分子包裹在所述脂质纳米颗粒中，形成包载核酸的脂质纳米颗粒。本发明确立了一种非侵入性、高效的脑靶向mRNA递送平台，为拓展mRNA疗法在神经领域的应用奠定了坚实基础。

一种调控mRNA转染的糖苷甾醇成分脂质纳米粒及其制备方法和应用

Resumen de: CN121868247A

一种调控mRNA转染的糖苷甾醇成分脂质纳米粒及其制备方法和应用属于药物制剂制备技术领域，纳米粒由DLin‑MC3‑DMA、DOPE、不同糖苷或甾醇及DSPE‑PEG‑GSH组成。不同糖苷或甾醇包括：苦杏仁苷Amy、β‑谷甾醇、豆甾醇Sti、人参皂苷Rg1、红景天苷Sal。豆甾醇可以提升LNP在脾脏的富集，人参皂苷可以调节免疫的作用增强抗肿瘤免疫效果，制备方法简单，所需设备均为常规设备，可实现大规模生产，因此具有良好的工业化应用价值和市场前景。

一种载药明胶纳米凝胶、仿生纳米凝胶及其制备方法和联合用药物与用途

Resumen de: CN121868225A

本发明提供了一种载药明胶纳米凝胶、仿生纳米凝胶及其制备方法和联合用药物与用途，属于生物医药技术领域。本发明将全反式维甲酸与吡非尼酮和明胶反应形成载药明胶纳米凝胶，协同抑制胰腺星状细胞活化与阻断促纤维化信号通路，实现对胰腺癌纤维化微环境的逆转；同时，将载药明胶纳米凝胶包覆于活化的胰腺星状细胞膜构建仿生纳米凝胶，使其具备主动靶向性，显著提升药物的递送效率与治疗效果；并将载药明胶纳米凝胶、仿生纳米凝胶和化疗药物联合用于治疗胰腺癌，具有显著抗肿瘤效果，且仿生纳米凝胶与吉西他滨的联合治疗具有协同增效的抗肿瘤作用。本发明凝胶实现了对胰腺癌致密纤维化微环境的有效调控，为胰腺癌的治疗提供了一种可行的新策略。

脂质化合物和脂质纳米颗粒组合物

Resumen de: CN121872965A

本公开提供了一种脂质化合物和脂质纳米颗粒组合物，所述脂质化合物具有如式I所示结构。本公开提供的脂质纳米颗粒粒径分布较好，包封率高，且递送效果优异，能够满足体内递送的需求。

用于将核酸递送至真核细胞的脂质

Resumen de: WO2025034764A1

Ionizable lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.

Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents

Resumen de: US20260102347A1

Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making said lipids. The lipids may have the structure of Formula A as defined herein. Formula A

Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents

Resumen de: US20260102357A1

The present disclosure relates to a sulfur-containing ionizable lipid or a pharmaceutically acceptable salt thereof that incorporates a dithioacetal or dithioketal moiety in one or more of its lipophilic chains. Further provided is a delivery vehicle, such as a lipid nanoparticle, comprising the ionizable lipid for the delivery of cargo, such as nucleic acid.

COMPOSITIONS AND METHODS FOR MARCO INHIBITION AND IMPROVED DRUG DELIVERY

Resumen de: US20260102468A1

According to various aspects of this disclosure, the present disclosure relates to combination therapies, methods, and kits comprising MARCO blocking agents and anti-cancer agents for improvement of nanoformulated drug delivery. Further, wherein a method of treating a tumor or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination therapy comprising a first agent and a second agent, wherein the first agent is capable of blocking the inter-action between a Macrophage Receptor with Collagenous Structure (MARCO) and a nanoparticle, and the second agent comprises an anti-cancer agent or an anti-tumor agent, and wherein at least the second agent is in the form of a nanoformulation, is disclosed.

AN ANALYTICAL METHOD USING LC-MS/MS PROTEOMICS TO CHARACTERIZE PROTEINS TRANSLATED FROM MRNA

Resumen de: US20260104425A1

The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translation; CFT) or inside a cell (cell-based translation; CBT) and analyzed using LC-MS/MS. The method provides advantages such as speed and convenience over traditional immunoassay-based methods of detecting translated proteins. Translation using CBT may be necessary in certain formulations of the mRNA, such as when the mRNA or a mixture of mRNAs is encapsulated inside a lipid nanoparticle.

LIPID COMPOSITION

Resumen de: US20260102346A1

Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition including a therapeutic agent and/or a prophylactic agent such as an RNA can be used for delivering the therapeutic agent and/or the prophylactic agent to a mammalian cell or organ, so as to, for example, regulate polypeptide, protein, or gene expression.

MRNA Therapies Including SIRP-ALPHA

Resumen de: US20260103501A1

Human SIRPa fusion proteins having an enhanced affinity to CD47 via increased binding valency. The human SIR-Pa fusion proteins described herein may form tetramer, hexamer, octamers, etc. These fusion proteins may be configured to form heterodimers with other fusion proteins, including C-C chemokine receptor type 4 (CCR4) binding fusion proteins.

NEOEPITOPE VACCINE DELIVERY VEHICLE AND METHODS OF MAKING THE SAME

Resumen de: AU2026202277A1

Abstract Disclosed therein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF NEUROPATHIC PAIN

Resumen de: US20260102427A1

The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO2 nanoparticles and/or aggregates of HfO2 nanoparticles, a composition comprising said nanoparticles and/or aggregates of nanoparticles, and their use in the treatment of NP.

TRANSDERMAL AMPHETAMINE COMPOSITIONS WITH LOW LEVELS OF CARBAMATE

Resumen de: US20260102362A1

Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal delivery of amphetamine.

Lipid Nanoparticles For Delivery Of Nucleic Acids, And Related Methods Of Use

Resumen de: AU2025271161A1

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors. ov o v

LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES

Resumen de: US20260102349A1

Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

COMPOSITIONS AND ARTICLES COMPRISING (NANO) DIAMOND PARTICLES

Resumen de: AU2026202273A1

Abstract Compositions and articles comprising diamond particles, such as nanodiamond-based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).

PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING

Resumen de: US20260102500A1

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and/or at least one lipid and/or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.

COMPOUND OR SALT THEREOF AND LIPID PARTICLES

Resumen de: US20260102348A1

An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, X represents —NR1— or —O—, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.

POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF

Resumen de: US20260103715A1

The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.

IONIZABLE LIPIDOID COMPOSITIONS AND THERAPEUTIC USES THEREOF

Resumen de: WO2026080557A1

Disclosed are lipidoid compounds having the structure of formula (I): or a salt thereof, wherein the groups are as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses pharmaceutical compositions comprising a lipidoid composition of the invention.

MODIFIED MYOFERLIN PROTEIN AND METHOD OF USE THEREOF TO INCREASE NANOPARTICLE PAYLOAD RELEASE

Resumen de: AU2024382503A1

A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.

LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF

Resumen de: AU2024359608A1

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

NANOBUBBLES FOR ULTRASOUND MEDIATED NUCLEIC ACID DELIVERY

Nº publicación: AU2024356988A1 16/04/2026

Solicitante:

CASE WESTERN RESERVE UNIV

Resumen de: AU2024356988A1

Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.